Jeff Yass’s CAMP4 Therapeutics CAMP Stock Holding History

Jeff Yass’s Portfolio CAMP Stock Details CAMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-336,047	Closed	-$1.48M	–	13447
2026 Q1	$1.48M	Buy	+336,047	New	+$1.6M	﹤0.01%	6914

Other funds holding CAMP

Jupiter Topco New York $245B AUM

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's CAMP Position: Q2 2026 in Review

Jeff Yass sold out of CAMP4 Therapeutics (CAMP) in Q2 2026, closing a stake of 336,047 shares — an estimated $1.48M sold.

Jeff Yass first reported a position in CAMP in Q1 2026 and held it in 1 quarter. The position peaked at $1.48M in Q1 2026. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

Jeff Yass reported no remaining CAMP4 Therapeutics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 336,047 CAMP4 Therapeutics shares in Q2 2026, an estimated $1.48M.
Jeff Yass first reported a position in CAMP4 Therapeutics in Q1 2026 and held it in 1 quarter.
Jeff Yass's CAMP4 Therapeutics position peaked at $1.48M in Q1 2026.
61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.